New oral antidiabetics – pharmaceutical chemical characterization of sodium-glucose cotransporter-2 inhibitors
References
- Wittmann I – Diabetológia jegyzet orvostanhallgatóknak, Pécsi Tudományegyetem, Pécs, 2020, 16-17.
- IDF Diabetes Atlas 2021–
https://diabetesatlas.org/atlas/tenth-edition - Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JC, Mbanya JC, Pavkov ME. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022 Jan 1;183:109119.
- Opie LH. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs. Cardiovascular drugs and therapy. 2014 Aug;28:331-4.
- Zhang Y, Liu ZP. Recent developments of C-aryl glucoside SGLT2 inhibitors. Current Medicinal Chemistry. 2016 Mar 1;23(8):832-49.
- Faillie JL. Pharmacological aspects of the safety of gliflozins. Pharmacological Research. 2017 Apr 1;118:71-81.
- Ramani J, Shah H, Vyas VK, Sharma M. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports. 2022 Aug 2:100074.
- Mazákné Kraszni M. A nem-inzulin antidiabetikumok gyógyszerészi kémiája-II. rész.
- Manoj A, Das S, Kunnath Ramachandran A, Alex AT, Joseph A. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review. Future Medicinal Chemistry. 2020 Nov;12(21):1961-90.
- Nakagaito M, Joho S, Ushijima R, Nakamura M, Kinugawa K. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circulation reports. 2019 Oct 10;1(10):405-13.
- Aguillon AR, Mascarello A, Segretti ND, de Azevedo HF, Guimaraes CR, Miranda LS, de Souza RO. Synthetic strategies toward SGLT2 inhibitors. Organic Process Research & Development. 2018 Mar 30;22(4):467-88.
- Nickerson B, Salisbury JJ, Harwood JW. Enantioselective analysis for L-pidolic acid in ertugliflozin drug substance and drug product by chiral gas chromatography with derivatization. Journal of Pharmaceutical and Biomedical Analysis. 2018 Sep 10; 159:212-6.
https://go.drugbank.com/drugs/DB08907 https://go.drugbank.com/drugs/DB06292 https://go.drugbank.com/drugs/DB09038 https://go.drugbank.com/drugs/DB11827 https://go.drugbank.com/drugs/DB11698 https://go.drugbank.com/drugs/DB11824 https://go.drugbank.com/drugs/DB12214 https://go.drugbank.com/unearth/q?searcher=drugs&query=sotegliflozin&button= https://go.drugbank.com/drugs/DB12236 https://go.drugbank.com/unearth/q?searcher=drugs&query=remogliflozin&button= - Fawzy MG, Hassan WE, Mostafa AA, Sayed RA. Different approaches for the assessment of greenness of spectrophotometric methodologies utilized for resolving the spectral overlap of newly approved binary hypoglycemic pharmaceutical mixture. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2022 May 5;272:120998.
- Moussa BA, Mahrouse MA, Fawzy MG. Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2018 Dec 5;205:235-42.
- Anjali M, Shreshta M, Prasanna R, Shrisha T, Kumar MS. Method development and validation of ertugliflozin and sitagliptin by using simultaneous equation method. Journal of Innovation in Pharmaceutical Sciences. 2019;3(1):22-8.
- Elnadi S, Abdalsabour S, Farouk M, Trabik YA. Fourier transform infrared spectroscopic, spectrofluorimetric assays of canagliflozin, and stability-indicating UV-spectrophotometric method for the simultaneous determination of canagliflozin and metformin. Journal of AOAC International. 2022 Jul 1;105(4):964-71.
- Azhakesan A, Kuppusamy S. Canagliflozin: A review with specific focus on analytical methods in biological matrices and pharmaceuticals. Reviews in Analytical Chemistry. 2022 Dec 2;41(1):287-300.
- Oh DW, Chon J, Kang JH, Han CS, Shin DH, Kim JY, Rhee YS, Chun MH, Kim DW, Park CW. Physicochemical characterization of dapagliflozin and its solid-state behavior in stress stability test. Drug development and industrial pharmacy. 2021 May 4;47(5):685-93.
- Liu M, Liu J, Wang Q, Song P, Li H, Wu S, Gong J. Quantitative analysis of low content polymorphic impurities in canagliflozin tablets by PXRD, NIR, ATR-FITR and Raman solid-state analysis techniques combined with stoichiometry. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2023 May 15;293:122458.
- Oh DW, Chon J, Kang JH, Han CS, Shin DH, Kim JY, Rhee YS, Chun MH, Kim DW, Park CW. Physicochemical characterization of dapagliflozin and its solid-state behavior in stress stability test. Drug development and industrial pharmacy. 2021 May 4;47(5):685-93.
- Abbas NS, Mohamed YA, Derayea SM, Omar MA, Saleh GA. Simple TLC–spectrodensitometric method for studying lipophilicity and quantitative analysis of hypoglycemic drugs in their binary mixture. Biomedical Chromatography. 2021 Nov;35(11):e5154.
- Itigimatha N, Chadchan KS, Yallur BC, Hadagali MD. Simple and sensitive RP-HPLC and UV spectroscopic methods for the determination of remogliflozin etabonate in pure and pharmaceutical formulations. Turkish Journal of Pharmaceutical Sciences. 2022 Apr;19(2):213.
- Elnadi S, Abdalsabour S, Abdalghany MF, Trabik YA. Stability indicating RP-HPLC and spectrophotometric methods for determination of gliflozins in their mixture with metformin. Journal of the Iranian Chemical Society. 2022 May;19(5):1723-35.
- Thakor NS, Amrutkar SV. A systematic review of Analytical profiles of SGLT2 inhibitors and their combinations for treatment of type 2 Diabetes Mellitus. Current Pharmaceutical Analysis. 2019 Dec 1;15(7):681-93.
- van der Aart-van der Beek AB, Wessels AMA, Heerspink HJL, Touw DJ – Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine, Journal of Chromatography B, 2020, 1152:1.
- Ganorkar SB, Sharma SS, Patil MR, Bobade PS, Dhote AM, Shirkhedkar AA. Pharmaceutical analytical profile for novel SGL-2 inhibitor: dapagliflozin. Critical Reviews in Analytical Chemistry. 2021 Nov 17;51(8):835-47.
- Maher HM, Abdelrahman AE, Alzoman NZ, Aljohar HI. Stability-indicating capillary electrophoresis method for the simultaneous determination of metformin hydrochloride, saxagliptin hydrochloride, and dapagliflozin in pharmaceutical tablets. Journal of Liquid Chromatography & Related Technologies. 2019 Apr 3;42(5-6):161-71.
- Gumieniczek A, Berecka A. Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological samples. Open Chemistry. 2016 Jan 1;14(1):215-42.019 Apr 3;42(5-6):161-71.
- Frampton JE. Empagliflozin: a review in type 2 diabetes. Drugs. 2018 Jul;78:1037-48.
- Gonzalez DE, Foresto RD, Ribeiro AB. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Revista da Associação Médica Brasileira. 2020 Jan 13;66:s17-24.
- Zhou Y, Fan J, Zheng C, Yin P, Wu H, Li X, Luo N, Yu X, Chen C. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2. Biomedicine & Pharmacotherapy. 2019 Jan 1;109:1327-38.
- Ramani J, Shah H, Vyas VK, Sharma M. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports. 2022 Aug 2:100074.
- Winkler G. Vércukorcsökkentő kezelés felnőttkori diabetesben. Gyógyszerészet, 2014, 58:399-409.
- Winkler G, Jermendy Gy. Dapagliflozin, a nátrium-glukóz kotranszporter-2 gátló vércukorcsökkentők első törzskönyvezett képviselője. Diabetologia Hungarica, 2013, 21(1):21-29.
- Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022 Sep 3;400(10354):757-67.
- Tang H, Xu C, Zhang P, Luo T, Huang Y, Yang X. A Profile of SGLT-2 inhibitors in Hyponatremia: The Evidence to Date. European Journal of Pharmaceutical Sciences. 2023 Mar 2:106415.
- van der Aart-van AB, Wessels AM, Heerspink HJ, Touw DJ. Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. Journal of Chromatography B. 2020 Sep 1;1152:122257.
- Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. Journal of the American Society of Hypertension. 2014 May 1;8(5):330-9.
- Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020 Mar 1;43(3):508-11.
- Koch B, Fuhrmann DC, Schubert R, Geiger H, Speer T, Baer PC. Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro. International Journal of Molecular Sciences. 2023 Jan 17;24(3):1811.
- Bendotti G, Montefusco L, Pastore I, Lazzaroni E, Lunati ME, Fiorina P. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. Journal of Endocrinological Investigation. 2023 Dec;46(12):2445-52.
- Salvatore T, Caturano A, Galiero R, Di Martino A, Albanese G, Vetrano E, Sardu C, Marfella R, Rinaldi L, Sasso FC. Cardiovascular benefits from gliflozins: effects on endothelial function. Biomedicines. 2021 Sep 29;9(10):1356.
- Vallon V. Renoprotective Effects of SGLT2 Inhibitors. Heart Failure Clinics. 2022 Oct 1;18(4):539-49.
- Sukiatno L, Kusuma IY, Samodra G. Cardioprotective and Renoprotective Effects of the Use of SGLT2 Inhibitors in Diabetes Mellitus Patients. InInternational Conference on Health and Medical Sciences (AHMS 2020) 2021 Jan 27 (pp. 121-127). Atlantis Press.
- Ravindran S, Munusamy S. Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. Journal of cellular physiology. 2022 Feb;237(2):1182-205.
- Belančić A, Klobučar S. Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms. Diabetology. 2023 Jul 4;4(3):251-8.
- Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, Kubozono T, Ohishi M. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacology and Toxicology. 2017 Dec;18:1-0
- Billing AM, Kim YC, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, Demir F, Kovalenko E, Lassé M, Dugourd A, Fallegger R. Metabolic communication by SGLT2 inhibition. Circulation. 2023 Dec 28.
- Gumieniczek A, Berecka-Rycerz A. Metabolism and chemical degradation of new antidiabetic drugs: a review of analytical approaches for analysis of glutides and gliflozins. Biomedicines. 2023 Jul 27;11(8):2127.
- Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opinion on Drug Metabolism & Toxicology. 2018 Dec 2;14(12):1287-302.
- Tirucherai GS, Lacreta F, Ismat FA, Tang W, Boulton DW. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2016 Jul;18(7):678-84.
- Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clinical pharmacokinetics. 2015 Oct;54:1027-41.
- Kasichayanula S, Liu X, LaCreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clinical pharmacokinetics. 2014 Jan;53:17-27.
- Gumieniczek A, Berecka-Rycerz A. Metabolism and chemical degradation of new antidiabetic drugs: a review of analytical approaches for analysis of glutides and gliflozins. Biomedicines. 2023 Jul 27;11(8):2127.
- Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences. 2016 Oct 10;93:244-52.
- Kaur P, Behera BS, Singh S, Munshi A. The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics. European Journal of Pharmacology. 2021 Aug 5;904:174169.
- Donnier-Maréchal M, Vidal S. Glycogen phosphorylase inhibitors: a patent review (2013-2015). Expert opinion on therapeutic patents. 2016 Feb 1;26(2):199-212.
- Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney International. 2011 Mar 1;79: S14-9.
- Dharia A, Khan A, Sridhar VS, Cherney DZ. SGLT2 inhibitors: the sweet success for kidneys. Annual Review of Medicine. 2023 Jan 27;74:369-84.
- Eickhoff MK, Dekkers CC, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, Faber J, Danser AJ, Gansevoort RT, Rossing P, Persson F. Effects of dapagliflozin on volume status when added to renin–angiotensin system inhibitors. Journal of clinical medicine. 2019 May 31;8(6):779.
- Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2022 Feb 1;127:154937.
- Palmer BF, Clegg DJ. Kidney-protective effects of SGLT2 inhibitors. Clinical Journal of the American Society of Nephrology. 2023 Feb 1;18(2):279-89.
- Frigy A, Germán-Salló M, Máthé L, Szabó M. Vércukorcsökkentő gyógyszerek biztonságossága szívelégtelenségben| The safety of anti-diabetic drugs in heart failure. Orvosi Hetilap. 2017;158(5):163-71.
- Meca AD, Tarțău LM, Popa EG, Gafițanu C, Crețeanu A, Bogdan M. Noi perspective asupra tratamentului cu antidiabetice orale, Farmacist Ro, 2019, 187(2):25-28
https://www.nps.org.au/radar/articles/sglt2-inhibitor-listings-indications-and-combinations - Jafar TH. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?. The Lancet. 2021 Jul 24;398(10297):283-4.
- Agenda Medicală 2024, Editura Medicală, București, 2024.
- MemoMed Ediția 30 – Memorator de farmacologie, Editura Universitară, București, 2024.
- Confederat LG, Condurache MI, Alexa RE, Dragostin OM. Particularities of urinary tract infections in diabetic patients: a concise review. Medicina. 2023 Sep 29;59(10):1747.
- Update MD. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum), 18 February 2019. Accessed online. 2021 May;6.
- Górriz JL, Navarro-González JF, Ortiz A, Vergara A, Nunez J, Jacobs-Cachá C, Martínez-Castelao A, Soler MJ. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrology Dialysis Transplantation. 2020 Jan 1;35(Supplement_1):i13-23.
- Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Translational and Clinical Pharmacology. 2020 Mar;28(1):17.
DOI: https://doi.org/10.2478/orvtudert-2023-0009 | Journal eISSN: 2537-5059 | Journal ISSN: 1453-0953
Language: English
Page range: 107 - 123
Published on: Jul 19, 2025
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Related subjects:
© 2025 Hajnal Kelemen, Petra-Edina Mărcuțiu, Adrienn Rausz, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.